RECRUITINGINTERVENTIONAL
68Ga-PSMA PET in the Renal Cell Carcinoma
A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma
About This Trial
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
Who May Be Eligible (Plain English)
Who May Qualify:
- 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
- In contrast-enhanced CT staging, suspicious metastases were found;
- There were no known peripheral or central venous problems;
- 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
- Signed the willing to sign a consent form form of voluntary participation in clinical trials.
Who Should NOT Join This Trial:
- Age ≤ 18 years old;
- Can't stand lying flat in PET / CT examination;
- There are contraindications for 68Ga PSMA ligands;
- In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
- Renal function is impaired or hemodialysis is in progress.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
* In contrast-enhanced CT staging, suspicious metastases were found;
* There were no known peripheral or central venous problems;
* 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
* Signed the informed consent form of voluntary participation in clinical trials.
Exclusion Criteria:
* Age ≤ 18 years old;
* Can't stand lying flat in PET / CT examination;
* There are contraindications for 68Ga PSMA ligands;
* In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
* Renal function is impaired or hemodialysis is in progress.
Treatments Being Tested
DIAGNOSTIC_TEST
PSMA PET
PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
Locations (9)
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Qinghai University Affiliated Hospital
Xining, Qinghai, China
Xijing Hospital
Xi'an, Shaan'xi, China
Weinan Central Hospital
Weinan, Shaanxi, China
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, China
Xijing 986 Hospital
Xi'an, Shaanxi, China
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Xianyang, Shaanxi, China
Affiliated Hospital of Yan'an University
Yan’an, Shaanxi, China